Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DX412
- Development stage
- Preclinical
- Lead developer
- DermaXon
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
DX412 is a preclinical-stage small molecule developed by DermaXon for the treatment of pain and pruritus (itch). It acts as an antagonist of the Transient Receptor Potential Vanilloid 3 (TRPV3) channel. TRPV3 is a non-selective cation channel highly expressed in keratinocytes and is known to play a significant role in skin barrier function, thermoreception, and the sensation of itch and pain. By inhibiting TRPV3, DX412 aims to modulate the signaling pathways involved in chronic pruritic conditions and inflammatory pain. The drug is part of DermaXon's broader focus on skin-related ion channels and retinoid metabolism pathways.
02
Targets
TRPV3 (Transient receptor potential vanilloid subtype 3)
Beyond the preview
Go deeper on DX412.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DX412.